First injection of cancer-killing oncolytic virus into human patient
- Antibiotics Unveiled as Potential Life Extenders Aiding Healthier Aging
- NK Cells: Unveiling a Multifaceted Medical Marvel for Stroke Recovery and Beyond
- Japan’s Shift to Regular COVID-19 Vaccination for Elderly
- Active Monitoring vs. Surgery for Moderate Cervical Lesions
- Probiotics Linked to Immune Suppression and Tumor Growth
- FDA Investigates T-Cell Malignancy Risk in CAR-T Cell Therapy
First injection of cancer-killing oncolytic virus into human patient
- FDA Investigates T-Cell Malignancy Risk in CAR-T Cell Therapy
- WHO Requests More Information from China on Pediatric Clustered Pneumonia
- First Chinese PD-1 Cancer Drug 30 Times More Expensive in U.S. than in China
- Cardiovascular Diseases Linked to COVID-19 Infections
- What is the difference between dopamine and dobutamine?
- How long can the patient live after heart stent surgery?
First injection of cancer-killing oncolytic virus into human patient.
Scientists announce injection of cancer-killing oncolytic virus into first human patient.
Scientists have injected the first human patient with a new cancer-killing virus. The virus, known as Vaxinia, has seen successful tests in animals. But the real test of its efficacy begins with this new clinical trial.
Scientists just injected a human patient with a cancer-killing virus
It’s easy to immediately think of something bad when you hear the word virus. After all, there are many deadly viruses out there.
Yet scientists are using a new cancer-killing virus called Vaxinia for experimental cancer treatments.
It is understood that the virus will be able to amplify the body’s immune response to cancer.
The virus itself has been specifically designed to kill cancer cells. And in previous animal experiments, scientists have seen very promising results. For more than a century, these viruses have been a “smoking gun” in the fight against cancer.
However, the success of these viruses has been very limited, to say the least.
This time, though, scientists have engineered cancer-killing viruses that not only harm cancer cells, but also make them more easily recognized by the body’s immune system.
The researchers hope this will help make the body’s response stronger, allowing it to fight back better.
Clinical trials of previous cancer drugs have also shown promising results. But beyond that, Vaxinia can help open new doors.
Early tests are promising
Of course, scientists tested the virus on animals before moving into human testing. In many cases, they saw great success in shrinking tumors in early animal and laboratory experiments.
The cancer-killing virus has been shown to reduce the size of lung, breast, ovarian, pancreatic and colon cancer tumors.
With this success, the scientists decided to proceed with human trials. Results seen in animals do not always translate directly to human patients.
There are obviously many reasons for this, but researchers hope the virus will improve a patient’s chances of fighting cancer.
Currently, Vaxinia will be tested in a Phase 1 trial with just 100 cancer patients. These patients had metastatic or advanced solid tumors, and each had tried at least two other treatments.
The researchers plan to use the drug in two different groups. The first group will receive Vaxinia only; the second group will get the cancer-killing virus and an immunotherapy drug.
Of course, Phase 1 trials are mostly about safety and finding the best dose.
Therefore, it may not demonstrate the overall efficacy of the virus. Yet this is an important next step in potentially finding alternative ways to fight cancer.
Currently, the trial is expected to be completed in early 2025. Therefore, it will be a while before seeing any final results.
First injection of cancer-killing oncolytic virus into human patient
(source:internet, reference only)
Disclaimer of medicaltrend.org
